Mycoplasma Infections Follow-up
- Author: Ken B Waites, MD; Chief Editor: Michael Stuart Bronze, MD more...
Further Outpatient Care
With appropriate treatment, uncomplicated episodes of M pneumoniae infection can be expected to resolve clinically within 7-10 days after onset.
Additional laboratory tests or radiographs are not usually necessary unless the illness does not respond to therapy, which would raise questions about the accuracy of the microbiological diagnosis or the possibility of chronic infection, which sometimes occurs.
The presence of extrapulmonary manifestations may warrant further workup and follow-up, depending on their nature and severity.
Improvement of pneumonia on chest radiographs may lag behind clinical improvement.
As with other bacterial infections, researchers have studied the value of antimicrobial prophylaxis for those in contact with persons with M pneumoniae infection.
Klausner et al (1998) reported that the administration of oral azithromycin plus standard epidemic control measures significantly reduced secondary attack rates following an outbreak of M pneumoniae pneumonia in a long-term care facility for mentally and developmentally disabled persons.
Previous studies using tetracyclines also demonstrated the efficacy of chemoprophylaxis in reducing transmission of M pneumoniae pneumonia.
Researchers have studied vaccines for many years, but they have not produced a vaccine for general use.
The fact that natural infection does not confer complete protective immunity against future infections makes this approach less promising.
Because of the endemicity of infection with M pneumoniae in susceptible populations, isolating patients is seldom practical and generally is not recommended.
Extrapulmonary complications may occur simultaneously with the onset of respiratory manifestations or as long as several days later. These complications may predominate to the extent that physicians may overlook a primary respiratory tract infection. Less than 10% of cases of M pneumoniae infections are associated with nonrespiratory illnesses, with the exception of various skin rashes, nausea, vomiting, and diarrhea, which may occur more often.
When extrapulmonary manifestations occur, however, they clearly can complicate the diagnosis and the recovery; they also make hospitalization more likely. Thus, a careful history and physical examination are essential, and follow-up is indicated.
Researchers believe that an autoimmune response plays a role in some extrapulmonary complications, but, because M pneumoniae has been isolated directly from cerebrospinal, pericardial, and synovial fluids and from other extrapulmonary sites, always consider direct invasion by this organism.
Extrapulmonary manifestations may include the following:
- Ascending (ie, Guillain-Barré) paralysis
- Transverse myelitis
- Cardiac arrhythmia
- Raynaud phenomenon
- Hemolytic anemia
- Disseminated intravascular coagulation
- Renal failure
- Erythema multiforme (ie, Stevens-Johnson syndrome)
- Erythema nodosum
- Ulcerative stomatitis
Most persons who are free of underlying conditions that may adversely affect the outcome of a respiratory tract infection can expect an excellent prognosis and a full return of pulmonary function.
For the minority of patients who have severe disease, diminished lung function may persist for weeks to months.
For the few persons who experience disseminated extrapulmonary symptoms, particularly neurologic manifestations, recovery can require weeks to months. While most recover fully and uneventfully, some persons with neurologic manifestations may experience long-term paralysis and reports describe cases of permanent neurologic deficits.
Muir MT, Cohn SM, Louden C, Kannan TR, Baseman JB. Novel toxin assays implicate Mycoplasma pneumoniae in prolonged ventilator course and hypoxemia. Chest. 2011 Feb. 139(2):305-10. [Medline].
Kannan TR, Provenzano D, Wright JR, Baseman JB. Identification and characterization of human surfactant protein A binding protein of Mycoplasma pneumoniae. Infect Immun. 2005 May. 73(5):2828-34. [Medline].
Techasaensiri C, Tagliabue C, Cagle M, Iranpour P, Katz K, Kannan TR. Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneumoniae strains. Am J Respir Crit Care Med. 2010 Sep 15. 182(6):797-804. [Medline].
Hardy RD, Coalson JJ, Peters J, Chaparro A, Techasaensiri C, Cantwell AM. Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin. PLoS One. 2009. 4(10):e7562. [Medline].
Talkington DF, Waites KB, Schwartz S, Besser RE. Emerging from obscurity: Understanding pulmonary and extrapulmonary syndromes, pathogenesis, and epidemiology of human Mycoplasma pneumoniae infections. Scheld WM, Craig WA, Hughes JM, eds. Emerging Infections. Washington, DC: ASM Press; 2001. Vol 5: 57-84.
Foy HM. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis. 1993 Aug. 17 Suppl 1:S37-46. [Medline].
Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med. 1997 Aug 11-25. 157(15):1709-18. [Medline].
Waites KB. New concepts of Mycoplasma pneumoniae infections in children. Pediatr Pulmonol. 2003 Oct. 36(4):267-78. [Medline].
Cunha BA. The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect. 2006 May. 12 Suppl 3:12-24. [Medline].
Cunha BA. Pneumonia Essentials. 3rd ed. Royal Oak, MI: Physicians Press; 2010.
Cunha BA. Liver involvement with Mycoplasma pneumoniae community-acquired pneumonia. J Clin Microbiol. Jul/2003. 41(7):3456-7. [Medline].
Parchuri S, Cunha BA. Mycoplasma pneumoniae community-acquired pneumonia: Diagnostic usefulness of the agglutination-dissociation test. Infect Dis Pract. 2006. 30:550-1.
Talkington DF, Shott S, Fallon MT, Schwartz SB, Thacker WL. Analysis of eight commercial enzyme immunoassay tests for detection of antibodies to Mycoplasma pneumoniae in human serum. Clin Diagn Lab Immunol. 2004 Sep. 11(5):862-7. [Medline].
Beersma MF, Dirven K, van Dam AP, Templeton KE, Claas EC, Goossens H. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". J Clin Microbiol. 2005 May. 43(5):2277-85. [Medline].
Winchell JM, Thurman KA, Mitchell SL, Thacker WL, Fields BS. Evaluation of three real-time PCR assays for detection of Mycoplasma pneumoniae in an outbreak investigation. J Clin Microbiol. 2008 Sep. 46(9):3116-8. [Medline].
Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother. 2009 May. 53(5):2160-2. [Medline]. [Full Text].
Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J. 2009 Aug. 28(8):693-6. [Medline].
Peuchant O, Ménard A, Renaudin H, Morozumi M, Ubukata K, Bébéar CM, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother. 2009 Jul. 64(1):52-8. [Medline].
Wolff BJ, Thacker WL, Schwartz SB, Winchell JM. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Chemother. 2008 Oct. 52(10):3542-9. [Medline]. [Full Text].
Suzuki S, Yamazaki T, Narita M, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2006 Feb. 50(2):709-12. [Medline].
Klausner JD, Passaro D, Rosenberg J, et al. Enhanced control of an outbreak of Mycoplasma pneumoniae pneumonia with azithromycin prophylaxis. J Infect Dis. 1998 Jan. 177(1):161-6. [Medline].
Ou G, Liu Y, Tang Y, You X, Zeng Y, Xiao J, et al. In vitro subminimum inhibitory concentrations of macrolide antibiotics induce macrolide resistance in Mycoplasma pneumoniae. Hippokratia. 2015 Jan-Mar. 19 (1):57-62. [Medline].